Of these, three demonstrated a significant interaction between HER2 status and treatment73,76,83, indicating that HER2+ breast cancer is associated with a greater benefit in terms of DFS and/or OS from anthracyclines than HER2− breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.